(Q41699385)

7 October 2017

title

Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis (English)

1 reference

7 October 2017

Meltzer EO

1

1 reference

7 October 2017

Casale TB

series ordinal

2

1 reference

7 October 2017

Nathan RA

series ordinal

3

1 reference

7 October 2017

Thompson AK

series ordinal

4

1 reference

7 October 2017

publication date

1 October 1999

1 reference

Annals of Allergy, Asthma & Immunology

7 October 2017

published in

1 reference

7 October 2017

volume

83

1 reference

7 October 2017

issue

4

1 reference

7 October 2017

page(s)

311-317

1 reference

Overview of comorbid associations of allergic rhinitis

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Learning impairment and allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

The role of outcome studies in allergy and clinical immunology.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Clinical comparison of histamine H1-receptor antagonist drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Interpretation of rhinoconjunctivitis quality of life questionnaire data

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962671-3

7 January 2021

10.1016/S1081-1206(10)62671-3

Identifiers

DOI

1 reference

7 October 2017

1 reference